alexa Isolation and Structural Elucidation of Novel Isomeric Process Related Impurities of Zolmitriptan | OMICS International | Abstract
ISSN: 2155-9872

Journal of Analytical & Bioanalytical Techniques
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Isolation and Structural Elucidation of Novel Isomeric Process Related Impurities of Zolmitriptan

Neelakandan K1,2*, Chaudhari Ashok1, Manikandan H2, Santosha N1, Prabhakaran B1 and Mukund Gurjar1

1API Research Centre, Emcure Pharmaceutical Limited, Hinjawadi, Pune, 411057, India

2Department of chemistry, Annamalai University, Chidhambaram, India

*Corresponding Author:
Neelakandan K
API Research Centre
Emcure Pharmaceutical Limited
Hinjawadi, Pune, 411057, India
Fax: +91 20 39821445
E-mail: [email protected]

Received date: March 11, 2013; Accepted date: April 05, 2013; Published date: April 08, 2013

Citation: Neelakandan K, Ashok C, Manikandan H, Santosha N, Prabhakaran B, et al. (2013) Isolation and Structural Elucidation of Novel Isomeric Process Related Impurities of Zolmitriptan. J Anal Bioanal Tech 4:165. doi: 10.4172/2155-9872.1000165

Copyright: © 2013 Neelakandan K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Four isomeric unknown impurities ranging from 0.08-0.12% were found in the purified sample of Zolmitriptan during the batch analysis by gradient reverse phase ultra performance liquid chromatography (UPLC) and their molecular weights determined by liquid chromatography mass spectroscopy (LC-MS) analysis. Subsequently, all the four impurities were isolated by flash chromatography followed by semi-preparative HPLC and characterized by 1H NMR, 13C NMR, 1H-1H COSY, HMBC, HSQC, MS spectroscopy and HPLC. The structures for these four impurities were assigned to be following
Isomeric Impurity-1: 4-((3-(2-(dimethylamino)ethyl)-4-(2-((oxazolidin-4-yl)methyl)phenyl)-1H-indol-5-yl)methyl) oxazolidin-2-one,
Isomeric Impurity-2: 4-((3-(2-(dimethylamino)ethyl)-2-(4-((oxazolidin-4-yl)methyl)phenyl)-1H-indol-5-yl)methyl) oxazolidin-2-one-,
Isomeric Impurity-3: 4-((3-(2-(dimethylamino)ethyl)-7-(4-((oxazolidin-4-yl)methyl)phenyl)-1H-indol-5-yl)methyl) oxazolidin-2-one,
Isomeric Impurity-4: 4-((3-(2-(dimethylamino)ethyl)-6-(4-((oxazolidin-4-yl)methyl)phenyl)-1H-indol-5-yl)methyl) oxazolidin-2-one
Isolation and characterization of impurities has helped us in improving the purity of API by removing these impurities using crystallization.

Keywords

Recommended Conferences
Share This Page
Top